28-Mar-2024
No headlines found.
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Globe Newswire (Tue, 5-Mar 8:00 AM ET)
Avadel Pharmaceuticals Issues Statement On Patent Litigation
Globe Newswire (Mon, 4-Mar 3:37 PM ET)
Globe Newswire (Mon, 4-Mar 6:30 AM ET)
Globe Newswire (Mon, 26-Feb 8:00 AM ET)
Avadel Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Globe Newswire (Wed, 7-Feb 8:00 AM ET)
Globe Newswire (Mon, 8-Jan 7:00 AM ET)
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
Avadel Pharmaceuticals PLC - American Depositary Shares Each Representing One Ordinary Share trades on the NASDAQ stock market under the symbol AVDL.
As of March 28, 2024, AVDL stock price climbed to $16.89 with 475,144 million shares trading.
AVDL has a beta of 1.11, meaning it tends to be more sensitive to market movements. AVDL has a correlation of 0.04 to the broad based SPY ETF.
AVDL has a market cap of $1.52 billion. This is considered a Small Cap stock.
Last quarter Avadel Pharmaceuticals PLC - American Depositary Shares Each Representing One Ordinary Share reported $19 million in Revenue and -$.32 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.03.
In the last 3 years, AVDL stock traded as high as $17.47 and as low as $1.05.
The top ETF exchange traded funds that AVDL belongs to (by Net Assets): ONEQ, GWX, AADR, BIB, IBRN.
AVDL has outperformed the market in the last year with a price return of +78.7% while the SPY ETF gained +33.6%. AVDL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.3% and +5.0%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
AVDL support price is $16.37 and resistance is $17.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVDL stock will trade within this expected range on the day.